Herold Advisors Inc. Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Herold Advisors Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,729 shares of the medical research company’s stock after buying an additional 240 shares during the quarter. Herold Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $918,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Meridian Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 2.2% during the 3rd quarter. Meridian Wealth Management LLC now owns 2,147 shares of the medical research company’s stock valued at $1,087,000 after acquiring an additional 47 shares during the last quarter. Strategic Blueprint LLC boosted its position in shares of Thermo Fisher Scientific by 7.8% during the 3rd quarter. Strategic Blueprint LLC now owns 1,124 shares of the medical research company’s stock valued at $569,000 after acquiring an additional 81 shares during the last quarter. Coastline Trust Co boosted its position in shares of Thermo Fisher Scientific by 0.7% during the 3rd quarter. Coastline Trust Co now owns 12,364 shares of the medical research company’s stock valued at $6,258,000 after acquiring an additional 88 shares during the last quarter. Coronation Fund Managers Ltd. boosted its position in shares of Thermo Fisher Scientific by 31.4% during the 3rd quarter. Coronation Fund Managers Ltd. now owns 96,509 shares of the medical research company’s stock valued at $48,850,000 after acquiring an additional 23,086 shares during the last quarter. Finally, DeDora Capital Inc. boosted its position in shares of Thermo Fisher Scientific by 9.8% during the 3rd quarter. DeDora Capital Inc. now owns 1,706 shares of the medical research company’s stock valued at $864,000 after acquiring an additional 152 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 over the last quarter. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TMO. Raymond James raised their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays raised their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday. HSBC raised their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $606.76.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $573.60 on Friday. The firm has a market cap of $218.95 billion, a P/E ratio of 36.79, a P/E/G ratio of 2.41 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The stock’s fifty day moving average price is $573.60 and its 200-day moving average price is $529.90.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.54 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.